Orbital Therapeutics

BMS Joins the In Vivo Cell Therapy Chase With $1.5B Orbital Therapeutics Acquisition

Startup Orbital Therapeutics brings Bristol Myers Squibb an in vivo cell therapy in development for treating autoimmune disease. With the deal, BMS joins AstraZeneca, AbbVie, and Gilead Sciences in turning to M&A as a way to get in vivo cell therapy assets and technologies.

By Frank Vinluan

BioPharma, Pharma

Orbital Therapeutics Raises $270M to Bring RNA-Based Medicines to New Heights

ARCH Venture Partners-backed Orbital Therapeutics’ is researching next-generation RNA medicines that offer advantages over currently available therapies. The startup’s three areas of focus are vaccines, protein replacement, and immunomodulation.

By Frank Vinluan